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A B S T R A C T
Purpose
To investigate whether anti–vascular endothelial growth factor therapy with bevacizumab prolongs
progression-free survival (PFS) when added to first-line letrozole as treatment of hormone
receptor–positive metastatic breast cancer (MBC).
Patients and Methods
Women with hormone receptor–positive MBC were randomly assigned 1:1 in a multicenter, open-
label, phase III trial of letrozole (2.5 mg orally per day) with or without bevacizumab (15 mg/kg
intravenously once every 3 weeks) within strata defined by measurable disease and disease-free
interval. This trial had 90% power to detect a 50% improvement in median PFS from 6 to 9 months.
Using a one-sided a = .025, a target sample size of 352 patients was planned.
Results
From May 2008 to November 2011, 350 women were recruited; 343 received treatment and were
observed for efficacy and safety. Median agewas 58 years (range, 25 to 87 years). Sixty-two percent
had measurable disease, and 45% had de novo MBC. At a median follow-up of 39 months, the
addition of bevacizumab resulted in a significant reduction in the hazard of progression (hazard ratio,
0.75; 95% CI, 0.59 to 0.96; P = .016) and a prolongation in median PFS from 15.6 months with
letrozole to 20.2 months with letrozole plus bevacizumab. There was no significant difference in
overall survival (hazard ratio, 0.87; 95% CI, 0.65 to 1.18; P = .188), with median overall survival of
43.9 months with letrozole versus 47.2 months with letrozole plus bevacizumab. The largest
increases in incidence of grade 3 to 4 treatment-related toxicities with the addition of bevacizumab
were hypertension (24% v 2%) and proteinuria (11% v 0%).
Conclusion
The addition of bevacizumab to letrozole improved PFS in hormone receptor–positive MBC, but this
benefit was associated with a markedly increased risk of grade 3 to 4 toxicities. Research on
predictive markers will be required to clarify the role of bevacizumab in this setting.
J Clin Oncol 34:2602-2609. © 2016 by American Society of Clinical Oncology
INTRODUCTION
Endocrine therapy (ET) is a relatively well-tolerated
treatment for hormone receptor–positive breast
cancer. Molecular diversity within this subgroup
can influence response to therapy.1-4 Specific inter-
actions between the estrogen receptor (ER) and cell
cycle survival5,6 and/or growth factor signaling
pathways7,8 may influence sensitivity to antiestrogen
therapy. Angiogenesis is a well-described hallmark
of malignancy.9,10 Furthermore, angiogenesis and
its vascular endothelial growth factor receptor
(VEGFR) signaling pathway are potential mecha-
nisms of resistance to ET that can be targeted with
selected newer agents.11,12
Angiogenesis is influenced by estrogen under
both physiologic and pathologic conditions.
Cyclical neovascularization of the premenopausal
female reproductive tract occurs in response
to changing levels of estradiol and other sex
steroids.13 In vitro and in vivo models demon-
strate a link between estradiol and endothelial cell
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proliferation,14-16 and these interactions are regulated by vascular
endothelial growth factor (VEGF).17,18 This stimulatory effect on
angiogenesis is also observed in preclinical models of breast
cancer.19,20 Furthermore, induction of VEGF is implicated as a
mechanism for the emergence of ET resistance.12 After the initial
vascular regression that follows hormone ablation therapy,
increasing VEGF levels have been associated with a wave of
angiogenesis and tumor neovascularization that supports tumor
regrowth.11
In patients with breast cancer, retrospective studies demon-
strate that increased tumor VEGF levels are associated with
decreased responsiveness to antiestrogen therapy and worse out-
come in all stages of this disease.21-24 Therefore, VEGF and the
VEGFR pathway may be an important target for treatment of
hormone receptor–positive breast cancer. Together, these obser-
vations suggest that antiangiogenic agents could be more effective
in a low-estrogen environment and that some of the proven efficacy
of antiestrogen therapy may be mediated via inhibition of
angiogenesis.
Bevacizumab, a humanized monoclonal antibody to VEGFA,
has activity in combinationwith chemotherapy in metastatic breast
cancer (MBC).25-29 Several trials have demonstrated the safety and
feasibility of combining ET with bevacizumab,30-33 but its impact
on outcomes remains uncertain. We conducted Cancer and
Leukemia Group B (CALGB, now known as Alliance) 40503, a
randomized phase III trial, to determine whether bevacizumab can
prolong progression-free survival (PFS) when added to first-line
ET with letrozole for hormone receptor–positive advanced-stage
breast cancer.
PATIENTS AND METHODS
Study Design
CALGB 40503 was initiated in 2008 as two parallel randomized trials to
compare ETalone with ET plus bevacizumab as first-line endocrine therapy
for hormone receptor–positive advanced-stage breast cancer: a phase III
study with letrozole as ET with a primary end point of PFS and a phase II
study with tamoxifen as ET with toxicity as the primary end point (results
will be reported separately). The study was supported by theNational Cancer
Institute (NCI) and CALGB/Alliance. This report provides the results from
the phase III study of letrozole with or without bevacizumab.
Patients
Eligible patients included women age 18 years or older with locally
advanced, unresectable, or metastatic breast cancer who were post-
menopausal (or receiving ovarian suppression with a leuteinizing
hormone-releasing hormone agonist). Patients could have either meas-
urable or nonmeasurable disease defined by Response Evaluation Criteria
in Solid Tumors (RECIST) version 1.0. Tumors were required to be positive
for the ER and/or progesterone receptor defined as $ 1%. Human epi-
dermal growth factor receptor 2 (HER2) status could be either positive or
negative. Patients may have received (neo)adjuvant chemotherapy
($ 12 months since completion of chemotherapy) and any duration of
adjuvant ET (# 4 weeks of ET for MBC before trial registration). At study
initiation, no prior chemotherapy for MBC was permitted; an amendment
in May 2010 allowed no more than one prior chemotherapy treatment for
MBC. Patients were required to have Eastern Cooperative Oncology Group
performance status # 1 and adequate bone marrow, hepatic, and renal
function, including a urine protein dipstick grade of# 1+ or urine protein:
creatinine (UPC) ratio of, 1. Patients were excluded if they had any of the
following: prior anti-VEGF or VEGFR tyrosine kinase therapy; major
(within 28 days) or minor (within 7 days) surgical procedures; known
brain or leptomeningeal metastasis; ongoing uncontrolled hypertension
(blood pressure: systolic. 150 mmHg and/or diastolic. 90mmHg); New
York Heart Association grade $ 2 congestive heart failure; history of
hypertensive crisis or encephalopathy; uncontrolled seizures despite
standard medication; history (within the past 6 months) of myocardial
infarction, unstable angina, stroke, abdominal fistula or abscess, or sig-
nificant bleeding episode; history of GI perforation within 12 months; any
nonhealing wound or fracture; or life expectancy # 12 weeks. Each
participant signed an institutional review board approved, protocol-
specific informed consent form in accordance with federal and institu-
tional guidelines.
Treatments and Dose Modifications
At activation in May 2008, patients were randomly assigned 1:1 in
double-blinded fashion to letrozole plus bevacizumab or letrozole plus
placebo. Patients were stratified by measurable disease (no/yes) and disease-
free interval (# 24 months/. 24 months). In May 2010, the study was
amended to include an open-label design with the intention of increasing
accrual. In August 2010, all patients who had started treatment during the
placebo-control design were unblinded, and accrual to the open-label trial
continued. Letrozole was administered at 2.5 mg orally once per day and
bevacizumabwas administered at 15mg/kg intravenously once every 3 weeks
(6 5 days) until disease progression or unacceptable toxicity. One cycle was
equivalent to 3 weeks. Restaging scans were performed every three cycles for
the first 18 cycles and then every four cycles until first disease progression.
The follow-up schedule was the same for both treatment arms.
No dose reductions were permitted for letrozole or bevacizumab.
Letrozole was held for grade . 3 hepatic dysfunction and resumed when
grade # 2 was reached. Bevacizumab was held for blood pressure
. 160/100 mmHg, urine protein$ 2 g per 24 hours or UPC$ 2 (could be
resumed upon reaching , 2 g per 24 hours or UPC , 2), grade 3 to 4
venous thromboembolic events (resumed once stable on anticoagulation),
and for patients who required surgery while on study. Bevacizumab was
permanently discontinued for grade $ 4 hypertension; nephrotic syn-
drome; reversible posterior leukoencephalopathy syndrome; grade $ 3
hemorrhage/congestive heart failure; grade $ 2 arterial thromboembolic
events; any grade GI perforation, leak, or fistula; wound dehiscence
requiring intervention; or grade$ 3 or 4 unspecified bevacizumab-related
adverse events (AEs). Bevacizumab was discontinued if held for toxicity
for . 8 weeks, but patients could continue on letrozole alone.
Study End Points
The primary efficacy end point was investigator-determined PFS
measured from study entry until first disease progression or death without
progression. Those who discontinued treatment before progression were
observed until first disease progression. Event-free patients were censored
at last clinical assessment. Secondary end points included objective
response and clinical benefit, PFS at 6 and 12 months, overall survival
(OS), and toxicity. For patients with measurable disease, objective response
rate (ORR) was defined as either complete response or partial response
without any requirement for confirmatory scans; clinical benefit rate
(CBR) was defined as complete response, partial response, or stable disease
for at least 24 weeks. Tumor assessments of response and progression were
defined according to RECIST v1.0. OS was measured from study entry
until death as a result of any cause or last contact. Toxicity was graded
according to NCI Common Toxicity Criteria version 3 and was reported
for grade 3 to 5 toxicities considered possibly, probably, or definitely
treatment related.
Statistical Analysis
A target enrollment of 352 patients and a final analysis at 274 PFS
events was planned to yield 90% power to detect an improvement in
www.jco.org © 2016 by American Society of Clinical Oncology 2603
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median PFS from 6 months in the control arm (letrozole alone) to
9 months (hazard ratio [HR], 0.66) in the experimental arm (letrozole plus
bevacizumab) using a one-sided a = .025. The study design assumed
22 months of accrual (16 patients per month) with 7 months of additional
follow-up to final analysis. The study was monitored biannually by a data and
safety monitoring board (DSMB) in accordance with NCI guidelines. Interim
analyses were preplanned to start at 137 PFS events (50% information) and to
consider stopping early only for futility. Nonbinding futility boundaries were
defined according to Freidlin and Korn34 using a one-sided a = .005.
Efficacy analyses followed protocol and used a modified intention-to-
treat approach that included all patients who began protocol therapy.
Time-to-event distributions were estimated by the Kaplan-Meier method.
The primary analysis of PFS and OS used a log-rank test stratified by
measurable disease and disease-free interval. HRs for letrozole plus bev-
acizumab compared to letrozole alone and 95% CIs were taken from
corresponding Cox proportional hazard models. Subgroup analyses were
exploratory and hypothesis generating, using univariate Cox models to
obtain HR estimates and 95% CIs without hypothesis testing. An arm
effect on ORR and CBR was tested in univariate logistic regression models
using a two-sided a = .05.
Study data were reviewed by the Alliance study data coordinator. Data
quality was confirmed by study chair review following CALGB policies.
Statistical analyses conducted by the Alliance Statistics and Data Center
were performed by using SAS v9.2 (SAS Institute, Cary, NC) and R 3.1.1.35
RESULTS
BetweenMay 2008 and November 2011, 350 patients were enrolled
in the phase III study of letrozole versus letrozole plus bev-
acizumab. The first interim analysis was reported to the DSMB in
June 2012 after 57% of the required events had occurred. After a
sixth interim analysis was reported in November 2014 (94% of
events), the DSMB released the study results. The results presented
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Fig 1. CONSORT diagram.
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here are based upon data available in the Alliance database as of
April 9, 2015, representing 42 months of follow-up after the
enrollment period and 264 PFS events (96% of required events).
Of the 350 patients enrolled, 136 registered before the May
2010 amendment, and 214 registered after the amendment. Two
patients were not randomly assigned because of an error. The
remaining 348 patients were randomly assigned to letrozole plus
bevacizumab (n = 174; 67 before the amendment and 107 after the
amendment) or letrozole (n = 174; 69 before the amendment and
105 after the amendment). One patient on the letrozole plus
bevacizumab arm and four patients on the letrozole arm were
randomly assigned but did not receive protocol treatment (Fig 1).
This left 343 patients (98%) who received treatment, 173 on the
letrozole plus bevacizumab arm and 170 on the letrozole arm;
those patients constituted the per protocol modified intention-to-
treat population for evaluating efficacy and safety (Fig 1). The test
of heterogeneity in PFS distributions between pre- and post-
amendment cohorts was not significant, so all analyses were
performed on the overall study population. Overall, 171 patients
(50%) died, 12 (3%) withdrew consent for follow-up for survival,
40 (12%) remained on protocol treatment, and 120 (35%) were
alive.
Patient Characteristics
Patient demographics and clinical and pathologic tumor
characteristics were well balanced between the two treatment arms
(Table 1). Nearly all tumors (98%) were ER positive; 4% were
HER2 positive. Median age was 58 years (range, 25 to 87 years),
62% had measurable disease, and 25% had bone-only metastases.
Forty-five percent of patients had de novo metastatic disease, and
44% had a disease-free interval longer than 2 years; these two
cohorts made up the majority of study patients. Nearly half the
patients (48%) received prior hormone therapy such as an aro-
matase inhibitor (23%) or tamoxifen (36%), and 40% received
prior chemotherapy.
Efficacy Analysis
There were 264 PFS events (letrozole, 138; letrozole plus
bevacizumab, 126), with a median follow-up for clinical assess-
ment of 39 months and a maximum follow-up of 70 months.
Results of the per-protocol primary stratified analysis showed an
observed HR of 0.75 (95% CI, 0.59 to 0.96), indicating that the
addition of bevacizumab resulted in a statistically significant
improvement in PFS over letrozole (one-sided P = .016; Fig 2A and
Appendix Table A1, online only). The addition of bevacizumab to
letrozole showed a 4.6-month prolongation in median PFS
(letrozole: 15.6 months [95% CI, 12.9 to 19.7 months]; letrozole
plus bevacizumab: 20.2 months [95% CI, 17.0 to 24.1 months]).
The observed medians of both arms were considerably longer
than anticipated in the initial study design. The proportion of
patients who were progression free at 6 months was 87% (95% CI,
82% to 93%) on the letrozole plus bevacizumab arm versus 77%
(95% CI, 71% to 83%) on the letrozole arm. At 12 months, 73%
(95% CI, 66% to 80%) versus 61% (95% CI, 54% to 68%),
respectively, were progression free. In exploratory subgroup
analyses, improvement in PFS with letrozole plus bevacizumab
versus letrozole did not vary substantially by age, de novo versus
Table 1. Patient Demographic and Tumor Characteristics
Characteristic
Letrozole +
Bevacizumab Letrozole
No. % No. %
No. randomly assigned and treated 173 100 170 100
Patient and clinical factors
Disease measurability
Nonmeasurable 67 39 63 37
Measurable 106 61 107 63
Race/ethnicity
White 154 89 155 91
Black 9 5 12 7
Asian 2 1 3 2
All other, including multiracial 8 5 0 0
Age, years
# 30 1 1 1 1
31-40 17 10 13 8
41-50 35 20 25 15
51-60 45 26 53 31
61-70 53 31 54 32
71-80 17 10 16 9
80+ 5 3 8 5
Median (range) 56 (25-85) 59 (29-87)
ECOG performance score
0 105 61 101 59
1 64 37 64 38
2 1 1 2 1
Missing 3 2 3 2
Disease-free interval, years
De novo 74 43 81 48
# 1 11 6 2 1
. 1 to # 2 10 6 7 4
. 2 75 43 77 45
Missing 3 2 3 2
No. of metastatic sites
1 55 32 56 33
2 56 32 60 35
3 41 24 28 16
4 14 8 14 8
5-6 4 2 9 5
Missing 3 2 3 2
Location of metastatic site
Bone only 41 24 43 25
Visceral only 41 24 41 24
Bone and visceral 88 51 83 49
Tumor features
ER status
Negative 0 0 1 1
Positive 170 98 166 98
Missing 3 2 3 2
PgR status
Negative 41 24 31 18
Positive 129 75 133 78
Missing 3 2 6 3
HER2 status
Negative 159 92 152 89
Positive 5 3 9 5
Missing 9 5 9 5
Prior endocrine therapy
Any 82 47 83 49
Tamoxifen 61 35 61 36
Aromatase inhibitor 36 21 43 25
Prior chemotherapy 72 42 65 38
Abbreviations: ECOG, Eastern Cooperative Oncology Group; ER, estrogen
receptor; HER2, human epidermal growth factor receptor 2; PgR, progesterone
receptor.
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recurrent disease, bone-only versus other sites of metastases, or
number of metastatic sites (Fig 3).
Secondary Analyses
Overall survival. At a median follow-up of 42 months
(maximum follow-up of 90 months), there were 171 deaths, 81 on
the letrozole plus bevacizumab arm and 90 on the letrozole arm.
OS did not differ significantly by arm (observed HR for letrozole
plus bevacizumab:letrozole, 0.87; 95% CI, 0.65 to 1.18; one-sided
P = .188). The median survival for the letrozole plus bevacizumab
armwas 47.2 months compared with 43.9 months for the letrozole
arm (Fig 2B and Appendix Table A1).
Tumor response. Of the 213 patients with measurable disease,
197 had baseline and sufficient repeat scans to assess objective
response (OR). The incidence of OR was significantly higher for
the letrozole plus bevacizumab arm compared with the letrozole
arm (69% v 49%; P = .004). Similarly, the incidence of clinical
benefit was higher for the letrozole plus bevacizumab arm com-
pared with the letrozole arm (80% v 62%; P , .001; Appendix
Table A2, online only).
AEs. At time of reporting, 303 patients (88%) had ended
protocol treatment, 150 on the letrozole plus bevacizumab arm and
153 on the letrozole arm. Of these, a higher proportion on the
letrozole plus bevacizumab arm ended therapy because of an AE
than on the letrozole arm (21 patients [14%] v two patients [1%],
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Fig 2. Kaplan-Meier time-to-event curves.
(A) Progression-free survival (PFS); (B) Overall
survival (OS). HR, hazard ratio. L, letrozole; B,
bevacizumab.
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respectively; Fig 1). Among all patients, including those still being
treated, the median number of cycles was 22 (maximum, 100) for
the letrozole plus bevacizumab arm and 17 (maximum, 88) for the
letrozole arm. Of patients randomly assigned to letrozole plus
bevacizumab, 76 (46%) had at least one cycle of bevacizumab
delayed because of toxicity.
Approximately 47% of patients receiving letrozole plus bev-
acizumab compared with 14% receiving letrozole had at least one
treatment-related AE of grade$ 3 (Table 2). Of these AEs, the most
common were hypertension (24% v 2%) and proteinuria (11% v
0%; Table 3). Most events occurred with , 3% frequency,
including thromboembolic events and hemorrhage. There were
two treatment-related deaths, one in each arm. One patient
randomly assigned to letrozole plus bevacizumab died after a CNS
hemorrhage; the other, who was randomly assigned to letrozole,
died as a result of pneumonia.
DISCUSSION
For women with hormone receptor–positive MBC, CALGB 40503
demonstrates that bevacizumab, an anti–VEGF A monoclonal
antibody, prolongs PFS from a median of 15.6 months with
letrozole alone to 20.2months, representing a 25% reduction in the
hazard of progression. Although the proportions of patients with
an objective response and clinical benefit were greater with
letrozole plus bevacizumab compared with letrozole alone, there
was no statistically significant difference in OS. These results are
consistent with both preclinical models and earlier clinical trial
results for bevacizumab with various chemotherapy agents.25-28
Toxicity for bevacizumab was also consistent with prior
experience.36 More patients in the bevacizumab-containing arm
experienced grade $ 3 AEs and discontinuation because of AEs,
but there were no unexpected or unusual toxicities seen in
combination with letrozole.
These results are similar to those reported in the Letrozole/
Fulvestrant and Avastin Study (LEA), which was the first multi-
center, open-label phase III trial to demonstrate an increase in PFS
(from 14.4 to 19.3 months) with the addition of bevacizumab to
first-line ET.32 However, in the LEA study, the difference in PFS did
not reach statistical significance (log-rank P = .126). In both trials,
similar benefits were observed with respect to ORR and CBR, but
neither trial showed a difference in OS. Both the CALGB 40503 and
the LEA trials showed bevacizumab-related toxicities, mainly
hypertension and proteinuria. In the LEA trial, eight patients
died during therapy or within 30 days of completing therapy. In
CALGB 40503, almost half the patients on letrozole plus bev-
acizumab had at least one treatment-related grade $ 3 AE;
however, there was no difference in treatment-related deaths.
The difference in treatment-related deaths may be secondary, in
part because of the higher proportion of patients older than age
70 years in the LEA trial. Given the increased bevacizumab-related
AEs, the value of the PFS benefit seen in CALGB 40503 must be
carefully weighed against the added bevacizumab expense, toxicity,
and inconvenience of intravenous administration as well as additional
monitoring for hypertension and proteinuria.
Disease status
Age, years
Site of metastasis
50
51−60
61−70
70+
Recurrent
De novo
Bone only
All others
92
98
107
33
155
182
84
253
73
79
78
24
124
139
60
203
Variable No.
treated
PFS
events
Univariate
HR (95% CI)
0.78 (0.49 to 1.24)
0.92 (0.59 to 1.43)
0.69 (0.44 to 1.08)
0.56 (0.25 to 1.27)
0.78 (0.55 to 1.11)
0.76 (0.55 to 1.06)
0.99 (0.59 to 1.64)
0.69 (0.53 to 0.91)
No. of metastases
1
2
3
4 or more
Total
111
116
69
41
343
79
91
59
34
264
0.90 (0.58 to 1.41)
0.69 (0.46 to 1.05)
0.53 (0.32 to 0.89)
1.01 (0.51 to 2.02)
0.76 (0.60 to 0.97)
Hazard Ratio
0.0 0.5 1.0 1.5 2.0
Fig 3. Exploratory subgroup analyses of
improvement in progression-free survival
(PFS) in the L + B arm over the L arm. HR,
hazard ratio. L, letrozole; B, bevacizumab.
Table 2. Maximum AEs Grade 3 or Higher With Treatment Attribution
AE
Letrozole +
Bevacizumab
(n = 173)
Letrozole
(n = 170)
No. % No. %
Any AE
Grade 3 71 42 21 13
Grade 4 7 4.2 1 0.6
Grade 5 1 0.6 1 0.6
Nonhematologic events
Grade 3 68 41 21 13
Grade 4 7 4.2 1 0.6
Grade 5 1 0.6 1 0.6
Hematologic events
Grade 3 5 3.0 0
Grade 4 0 0
Grade 5 0 0
Treatment-related death 1* 0.6 1† 0.6
NOTE. Reported adverse events (AEs) were graded by using the National
Cancer Institute Common Terminology Criteria for Adverse Events version 3
with attribution possibly, probably, or definitely related to treatment.
*CNS hemorrhage.
†Pneumonia.
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Our observation of a PFS improvement without an OS benefit
is similar to results from prior chemotherapy-based studies testing
bevacizumab in MBC.25-28,37 CALGB 40503 was activated in 2008,
soon after the US Food and Drug Administration granted accel-
erated approval of bevacizumab for the treatment of HER2-
negative MBC in combination with first-line chemotherapy. In
2011, the Food and Drug Administration rescinded this approval.38
Since then, several phase III (neo)adjuvant trials have been negative
in patients with differing pathologic and molecular subtypes of
early-stage breast cancer, including those with HER2-negative,39,40
triple-negative,41 or HER2-positive disease.42 One exception is
NSABP B40 (Chemotherapy With or Without Bevacizumab in
Treating WomenWith Stage I, Stage II, or Stage IIIA Breast Cancer
That Can Be Removed By Surgery), which demonstrated an
increase in OS with the addition of neoadjuvant bevacizumab.43 To
date, a biomarker that defines a subset of patients most likely to
benefit from bevacizumab has not been identified.
Broadly, these data challenge the assumption that PFS is a
surrogate for OS in MBC or that PFS alone can be used in all
settings to identify superior treatment options. Given the extent
of data for bevacizumab across multiple stages and settings in
breast cancer, it is clear that the statistically significant
improvement in PFS that our trial was designed to detect is not,
in itself, sufficient to change standards of care. Were it associated
with improved survival, a different (and lesser) toxicity profile,
or different (and lesser) costs, then perhaps our assessment
would change.
It is noteworthy that the median PFS for the CALGB 40503
control arm (letrozole alone, 15.6 months) substantially exceeded
the projection based on literature available when the study was
designed.44-47 Almost half the patients achieved an OR to therapy.
These results are consistent with other recently reported phase III
first-line ET trials32,48 that enrolled similar proportions of hor-
mone receptor–positive patients with MBC with de novo and/or
ET-naı¨ve metastatic disease. The favorable outcome for these
endocrine-sensitive subgroups should have an impact on PFS event
rate estimates and future first-line ET clinical trial design. Given
continued efforts to develop therapies that delay the emergence of
endocrine resistance in hormone receptor–positive MBC,49-51 this
observation has immediate relevance. With added inconvenience
and toxicities that can be a burden for some, it is important for us
to define hormone receptor–positive populations that are more
likely to benefit from these newer targeted agents and to identify
those patients who may do well with ET alone.
Given the positive results of CALGB 40503 on our primary
end point, we will refine subgroup selection by using patient and
tumor characteristics to potentially identify factors in both the
control and experimental arms that are predictive of benefit from
ET alone or with bevacizumab. Results may inform the design of
new trials to test bevacizumab or other classes of targeted therapies
added to ET.
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Table A1. Observed Effect of Treatment Arm on PFS and OS
Parameter
PFS OS
Letrozole + Bevacizumab Letrozole
Letrozole + Bevacizumab
v Letrozole
Letrozole + Bevacizumab Letrozole
Letrozole + Bevacizumab
v Letrozole
HR 95% CI P* HR 95% CI P*
No. of patients 173 170 173 170
No. of events 126 138 81 90
Median, months 20.2 15.6 47.2 43.9
0.75 0.59 to 0.96 .016 0.87 0.65 to .18 .188
Abbreviations: HR, hazard ratio; OS, overall survival; PFS, progression-free survival.
*One-sided.
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Table A2. Incidence of OR and CB by Arm for Measurable Tumors
Characteristic
Letrozole + Bevacizumab Letrozole
No. % 95% CI No. % 95% CI
No. with measurable disease 106 100 107 100
No. assessable for response* 98 92 99 93
No. with measurable disease and assessable for response 98 100 99 100
Complete response 4 4 7 7
Partial response 64 65 42 42
Stable disease, weeks 22 22 34 34
, 24 12 22
$ 24 10 12
Progression 8 8 16 16
Objective tumor response† 68 69 60 to 78 49 49 40 to 59
CB‡ 78 80 71 to 86 61 62 52 to 71
Abbreviations: CB, clinical benefit; ECOG, Eastern Cooperative Oncology Group; OR, objective response.
*Sufficient tumor information was available to assess response.
†Objective tumor response is defined as complete response or partial response.
‡Clinical benefit is defined as complete response, partial response or stable disease for at least 24 weeks.
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